중등도에서 중증의 플라크 건선 환자를 대상으로 한 ORKA-001의 용량 탐색 연구 (EVERLAST-B)
중등도에서 중증의 플라크 건선 환자를 대상으로 한 ORKA-001의 다기관, 무작위배정, 이중눈가림, 위약대조, 용량탐색 임상시험
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.
The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.
The study will consist of 4 periods:
- Screening Period of up to 6 weeks
- Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
- Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
- Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Baden-Wuerrtemberg
-
Heidelberg, Baden-Wuerrtemberg, 독일, 69120
- Oruka Therapeutics Investigative Site
-
-
Hesse
-
Frankfurt am Main, Hesse, 독일, 60590
- Oruka Therapeutics Investigative Site
-
-
Lower Saxony
-
Bad Bentheim, Lower Saxony, 독일, 48455
- Oruka Therapeutics Investigative Site
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, 독일, 24105
- Oruka Therapeutics Investigative Site
-
-
-
-
Arizona
-
Phoenix, Arizona, 미국, 85032
- Oruka Therapeutics Investigative Site
-
-
Arkansas
-
North Little Rock, Arkansas, 미국, 72117
- Oruka Therapeutics Investigative Site
-
-
California
-
Los Angeles, California, 미국, 90045
- Oruka Therapeutics Investigative Site
-
Los Angeles, California, 미국, 90024
- Oruka Therapeutics Investigative Site
-
San Diego, California, 미국, 92123
- Oruka Therapeutics Investigative Site
-
-
Florida
-
Miami, Florida, 미국, 33126
- Oruka Therapeutics Investigative Site
-
-
Illinois
-
Rolling Meadows, Illinois, 미국, 60008
- Oruka Therapeutics Investigative Site
-
-
Indiana
-
Plainfield, Indiana, 미국, 46168
- Oruka Therapeutics Investigative Site
-
-
Maryland
-
Rockville, Maryland, 미국, 20850
- Oruka Therapeutics Investigative Site
-
-
New York
-
Kew Gardens, New York, 미국, 11415
- Oruka Therapeutics Investigative Site
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27516
- Oruka Therapeutics Investigative Site
-
-
Ohio
-
Cleveland, Ohio, 미국, 44106
- Oruka Therapeutics Investigative Site
-
Mason, Ohio, 미국, 45040
- Oruka Therapeutics Investigative Site
-
-
Oregon
-
Portland, Oregon, 미국, 97201
- Oruka Therapeutics Investigative Site
-
Portland, Oregon, 미국, 97210
- Oruka Therapeutics Investigative Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- Oruka Therapeutics Investigative Site
-
-
Texas
-
Frisco, Texas, 미국, 75033
- Oruka Therapeutics Investigative Site
-
Houston, Texas, 미국, 77004
- Oruka Therapeutics Investigative Site
-
Webster, Texas, 미국, 77598
- Oruka Therapeutics Investigative Site
-
-
Virginia
-
Norfolk, Virginia, 미국, 23502
- Oruka Therapeutics Investigative Site
-
-
-
-
Barcelona
-
Badalona, Barcelona, 스페인, 08916
- Oruka Therapeutics Investigative Site
-
Barcelona, Barcelona, 스페인, 08041
- Oruka Therapeutics Investigative Site
-
-
Madrid
-
Madrid, Madrid, 스페인, 28002
- Oruka Therapeutics Investigative Site
-
Madrid, Madrid, 스페인, 28046
- Oruka Therapeutics Investigative Site
-
-
-
-
British Columbia
-
Surrey, British Columbia, 캐나다, V3R 6A7
- Oruka Therapeutics Investigative Site
-
Surrey, British Columbia, 캐나다, V3V 0C6
- Oruka Therapeutics Investigative Site
-
-
New Brunswick
-
Fredericton, New Brunswick, 캐나다, E3B 1G9
- Oruka Therapeutics Investigative Site
-
-
Ontario
-
Ajax, Ontario, 캐나다, L1S 7K8
- Oruka Therapeutics Investigative Site
-
Markham, Ontario, 캐나다, L3P 1X3
- Oruka Therapeutics Investigative Site
-
Peterborough, Ontario, 캐나다, K9J 5K2
- Oruka Therapeutics Investigative Site
-
-
Quebec
-
Montreal, Quebec, 캐나다, HZX 2V1
- Oruka Therapeutics Investigative Site
-
Québec, Quebec, 캐나다, G1V 4X7
- Oruka Therapeutics Investigative Site
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Participants ≥ 18 years of age
-
Have a diagnosis of plaque psoriasis for > 6 months
-
Have moderate-to-severe chronic plaque psoriasis defined as:
- BSA ≥ 10%, and
- PASI ≥ 12, and
- IGA score of ≥ 3 on a 5-point scale
-
Candidate for systemic therapy or phototherapy
-
Women of childbearing potential must have a negative pregnancy test.
Exclusion Criteria:
- Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
- Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
- History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
- A known hypersensitivity to any components of the ORKA-001 drug product
- Women who are breastfeeding or plan to breastfeed during the study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: (Induction Period - Arm 1) ORKA-001
Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
실험적: (Induction Period - Arm 2) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
실험적: (Induction Period - Arm 3) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
위약 비교기: (Induction Period - Arm 4) Placebo
Participants will receive Placebo per protocol Induction regimen. |
Placebo administered by subcutaneous (SC) injection |
|
실험적: (Maintenance Period - Arm 1) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
실험적: (Maintenance Period - Arm 2) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
위약 비교기: (Maintenance Period - Arm 3) Placebo
Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response. |
Placebo administered by subcutaneous (SC) injection |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16
기간: Week 16
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16
기간: Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16
기간: Week 16
|
Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16
기간: Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100
기간: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100
기간: Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100
기간: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100
기간: Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100
기간: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
기간: Day 1 through Week 100
|
Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms |
Day 1 through Week 100
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- ORKA-001-114
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .